Dakar, April 6 APS) – In a statement issued Tuesday, the Mo Ibrahim Foundation called for “a series of urgent measures” to increase access to Covid-19 vaccines in Africa.
The text, signed by members of the Foundation’s board of directors, members of the Ibrahim Prize Committee and Ibrahim Prize winners, recommends “a series of urgent actions to strengthen Africa’s access to vaccines”.
Ensuring equal and equal access to vaccines is a global safety issue and a matter of common interest. We all know that if the virus is not effectively eliminated everywhere, it will continue to spread and mutate.
The signatories of the declaration call for an “immediate and concerted commitment to promote the fairness of immunization. This includes allocating additional financial resources to the countries most in need and strengthening local vaccine production capacity.”
“All of these topics will be the subject of the Foundation’s forthcoming report on ‘Africa and COVID-19: A Year Later’ and will be at the heart of the Ibrahim Forum’s 2021 Weekend Weekend Forum, which will take place from almost 3 to 5 June 2021,” the statement said. the source itself.
Africa has “received only 0.5% of the distributed vaccine doses, according to the latest figures,” although the continent is one of the “most vulnerable in the world” and “home to 17% of the world’s population,” according to the Mo Ibrahim Foundation.
The World Health Organization (WHO) heads an international mechanism called the Covax Initiative, which includes a funding mechanism to help 92 disadvantaged countries.
But despite this initiative, inequality in access to Kovid vaccines between rich and poor countries is “growing” and becoming “grotesque,” WHO Director-General Tedros Adhan Gebrees said on March 22.
The WHO boss warned that if this situation continues, the world risks seeing the virus take the world hostage for several more years.
At the end of March and according to international media, more than 455 million doses were administered worldwide, including more than a quarter in the United States.
According to the same data, worldwide only 0.1% of the doses administered worldwide were in “low-income” countries, while “high-income” countries (16% of the world’s population) concentrate more than half administered doses (56%).